Atara Biotherapeutics Inc
-
Ticker
ATRA
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 201-500 Employees
- Based in South San Francisco, California
Atara Biotherapeutics Inc. is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel
…More® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California.
Atara Biotherapeutics Inc
Most Recent Responsibility Report
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived Atara Biotherapeutics Inc Sustainability Report, Atara Biotherapeutics Inc Corporate Social Responsibility Report, Atara Biotherapeutics Inc CSR Report, Atara Biotherapeutics Inc Corporate Responsibility, Atara Biotherapeutics Inc CR Report, Atara Biotherapeutics Inc Citizenship Report, Atara Biotherapeutics Inc ESG Report, and Atara Biotherapeutics Inc Environmental Report online.